New Nivolumab Dosing Schedules Approved in Europe

April 25, 2018 – The European Commission has approved a 4-week dosing schedule for nivolumab for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC), according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor. The commission specifically approved a 4-week dosing regimen with 480 mg of nivolumab for these indications. Additionally, the commission approved replacing weight-based dosing … (leggi tutto)